165 related articles for article (PubMed ID: 36329030)
1. LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the EZH2-E-cadherin/RHOB pathway.
Lei C; Li S; Fan Y; Hua L; Pan Q; Li Y; Long Z; Yang R
Cancer Biol Ther; 2022 Dec; 23(1):1-13. PubMed ID: 36329030
[TBL] [Abstract][Full Text] [Related]
2. YBX1/lncRNA SBF2-AS1 interaction regulates proliferation and tamoxifen sensitivity via PI3K/AKT/MTOR signaling in breast cancer cells.
Hussain SA; Venkatesh T
Mol Biol Rep; 2023 Apr; 50(4):3413-3428. PubMed ID: 36754932
[TBL] [Abstract][Full Text] [Related]
3. Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway.
Li Z; Yu D; Li H; Lv Y; Li S
Int J Oncol; 2019 Mar; 54(3):1033-1042. PubMed ID: 30628639
[TBL] [Abstract][Full Text] [Related]
4. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway.
Liu G; Zhao X; Zhou J; Cheng X; Ye Z; Ji Z
Cell Physiol Biochem; 2018; 48(1):371-384. PubMed ID: 30016766
[TBL] [Abstract][Full Text] [Related]
5. The carcinogenic complex lncRNA DUXAP8/EZH2/LSD1 accelerates the proliferation, migration and invasion of colorectal cancer.
Gong A; Huang Z; Ge H; Cai Y; Yang C
J BUON; 2019; 24(5):1830-1836. PubMed ID: 31786844
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of long non-coding RNA DUXAP8 suppresses proliferation, metastasis and EMT by modulating miR-498 through TRIM44-mediated AKT/mTOR pathway in non-small-cell lung cancer.
Ji X; Tao R; Sun LY; Xu XL; Ling W
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3152-3165. PubMed ID: 32271433
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of cannabinoid receptor 2 is associated with human breast cancer proliferation, apoptosis, chemosensitivity and prognosis via the PI3K/Akt/mTOR signaling pathway.
Song Q; Zhang W; Shi D; Zhang Z; Zhao Q; Wang M; Huang M; Meng J; Cui W; Luo X
Cancer Med; 2023 Jun; 12(12):13538-13550. PubMed ID: 37220224
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.
Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
Cell Death Dis; 2013 Oct; 4(10):e875. PubMed ID: 24157869
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of Long Noncoding RNA_GAS5 Suppresses Cell Proliferation and Metastasis in Laryngeal Cancer via Regulating PI3K/AKT/mTOR Signaling Pathway.
Liu W; Zhan J; Zhong R; Li R; Sheng X; Xu M; Lu Z; Zhang S
Technol Cancer Res Treat; 2021; 20():1533033821990074. PubMed ID: 33641529
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of lncRNA HAGLROS enhances the development of nasopharyngeal carcinoma via modulating miR-100/ATG14 axis-mediated PI3K/AKT/mTOR signals.
Zhang W; Zhang Y; Xi S
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3043-3052. PubMed ID: 31334669
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
Ma T; Chen H; Wang P; Yang N; Bao J
Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
[No Abstract] [Full Text] [Related]
14. LncRNA RHPN1-AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p/EGFR/PI3K/AKT/mTOR signaling pathway.
Ma X; Ren H; Zhang Y; Wang B; Ma H
Environ Toxicol; 2022 Dec; 37(12):3013-3027. PubMed ID: 36125241
[TBL] [Abstract][Full Text] [Related]
15. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer.
Abu-Alghayth MH; Khan FR; Belali TM; Abalkhail A; Alshaghdali K; Nassar SA; Almoammar NE; Almasoudi HH; Hessien KBG; Aldossari MS; Binshaya AS
Pathol Res Pract; 2024 Mar; 255():155180. PubMed ID: 38330621
[TBL] [Abstract][Full Text] [Related]
17. The Pseudogene DUXAP8 Promotes Colorectal Cancer Cell Proliferation, Invasion, and Migration by Inducing Epithelial-Mesenchymal Transition Through Interacting with EZH2 and H3K27me3.
He W; Yu Y; Huang W; Feng G; Li J
Onco Targets Ther; 2020; 13():11059-11070. PubMed ID: 33149618
[TBL] [Abstract][Full Text] [Related]
18. LncRNA LINC-PINT Inhibits Malignant Behaviors of Laryngeal Squamous Cell Carcinoma Cells via Inhibiting ZEB1.
Yang X; Miao S; Mao X; Xiu C; Sun J; Pei R; Jia S
Pathol Oncol Res; 2021; 27():584466. PubMed ID: 34257531
[No Abstract] [Full Text] [Related]
19. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.
Wu Q; Ma J; Wei J; Meng W; Wang Y; Shi M
Mol Oncol; 2021 Jan; 15(1):299-316. PubMed ID: 32460412
[TBL] [Abstract][Full Text] [Related]
20. The Pseudogene DUXAP8 Promotes Non-small-cell Lung Cancer Cell Proliferation and Invasion by Epigenetically Silencing EGR1 and RHOB.
Sun M; Nie FQ; Zang C; Wang Y; Hou J; Wei C; Li W; He X; Lu KH
Mol Ther; 2017 Mar; 25(3):739-751. PubMed ID: 28131418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
